Last reviewed · How we verify
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody in patients with advanced hepatocellular carcinoma (HCC)
Details
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | PHASE2 |
| Status | WITHDRAWN |
| Start date | Mon Dec 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hepatocellular Carcinoma
Interventions
- Lenvatinib
- PD-1 antibody
Countries
China